Clinical trial
A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early…
NCT05310071 · Biogen, Industry · Terminated
Key facts
| NCT number | NCT05310071 |
|---|---|
| Title | A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease |
| Official title | A Phase 3b/4 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Verify the Clinical Benefit of Aducanumab (BIIB037) in Participants With Alzheimer's Disease |
| Acronym | ENVISION |
| Lead sponsor | Biogen, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Alzheimer's Disease |
| Intervention type | Drug |
| Interventions | Aducanumab, Placebo |
| Enrollment | 1,027 |
| Start date | Jun 2, 2022 |
| Primary completion | Aug 12, 2024 |
| Completion | Aug 12, 2024 |
| First posted | Apr 4, 2022 |
| Last update posted | Apr 23, 2025 |
| Countries | Australia, Belgium, Brazil, Canada, Finland, France, Germany, Italy, Japan, Mexico, Poland, South Korea and 4 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: